EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Neurologic Complications of Cancer Immunotherapy

Alexandra Balshi, Prashanth Rajarajan, Caleb R.S. McEntire, Giovanna S. Manzano

Seminars in Neurology · 2026-08-26

DOI: 10.1055/a-2936-4931 ↗
AbstractBibliografische Angaben

Abstract

Abstract The use of oncologic-directed immunotherapies, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell (CAR-T) therapy, has risen exponentially in recent years. Although these therapies have been shown to improve long-term survival and quality of life in responsive patients, their nonspecific immune system activation can lead to unanticipated neurotoxicity, among other complications. Immune-related adverse events (irAEs) may involve any location in the entire neuroaxis, posing a diagnostic challenge, and may cause severe, life-threatening complications. ICI-related neurotoxicities may include peripheral neuropathies, myositis, myasthenia gravis, encephalitis, aseptic meningitis, myelitis, and demyelinating disorders. CAR-T therapies carry a comparatively higher risk of neurologic irAEs, most notably immune effector cell–associated neurotoxicity syndrome. In this review, neurotoxicity syndromes associated with ICI and CAR-T therapies are outlined, along with diagnostic approaches and management strategies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →